Slope today announced the closing of a $20 million Series A financing, led by global venture capital firm New Enterprise Associates, Inc. (NEA), to accelerate go-to-market efforts and further expand into decentralized and direct-to-patient clinical trials.
It’s 4:45 PM on a Friday and a CRA gets a call. One of their Research Sites is scrambling. They have a patient coming in on Monday, and just discovered that all of the kits they need for a critical baseline visit are expired.
Inventory surrounds us. It’s in your house, at your gas station, in your grocer’s freezer, and on the shelves of your Research Site’s supply closets and pharmacy. Inventory is something that demands attention and careful management.
It’s 4:45 PM on a Friday and a CRA gets a call. One of their Research Sites is scrambling. They have a patient coming in on Monday, and just discovered that all of the kits they need for a critical baseline visit are expired.
Inventory surrounds us. It’s in your house, at your gas station, in your grocer’s freezer, and on the shelves of your Research Site’s supply closets and pharmacy. Inventory is something that demands attention and careful management.
Slope today announced the closing of a $20 million Series A financing, led by global venture capital firm New Enterprise Associates, Inc. (NEA), to accelerate go-to-market efforts and further expand into decentralized and direct-to-patient clinical trials.
